ANNORA PHARMA PRIVATE LIMITED

Location

Telangana

Founded

2015-11-26

Risk Signals

4 news mentions monitored

Industry Context

This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Guided Missile Space Vehicle Parts and Auxiliary Equipment, Not Elsewhere Classified), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.

Filter risk signals by topic

Select a theme below to explore the company’s news mentions in specific risk areas.

Recent Articles about ANNORA PHARMA PRIVATE LIMITED

Live alerts from global media, monitored by Business Radar

UCB Wins Patent Order Blocking Copies of Briviact Epilepsy Drug

2023-08-16 (bloomberglaw.com)

UCB Wins Patent Order Blocking Copies of Briviact Epilepsy Drug

UCB SA won a decision blocking copies of Briviact until 2026, as a federal judge upheld the validity of a patent three generic-drug makers had conceded their proposed versions of the epilepsy treatment infringe.

Read more

Never miss a headline about ANNORA PHARMA PRIVATE LIMITED

Set up smart alerts with Business Radar and receive real-time updates on any new risk signal or major news story.

  • ✔️ Used by 100+ compliance teams and analysts
  • ✔️ Covers 154M+ sources in 40+ languages